1. Stories /
  2. Healthcare /
  3. Xellia /
Invested >$100m in R&D
Axellia Køben Cfc0231 300Dpicmyk CROP
Xelia Logo NEW LHS

Transformed from a supplier of niche active pharmaceutical ingredients to a fully-integrated speciality pharmaceutical company

Denmark Flag New
Investment date

2008 - 2013

Good to great


money multiple
Icon 1 (1)


invested in R&D during investment
Icon 3 (1)

Successfully grew and transitioned the business to become a leader in the supply of key anti-infective products


EBITDA growth per annum
Icon 3 (1)

Invested more than $100m in R&D and capacity expansion across its global manufacturing network

Key events under our ownership

Established a high-calibre management team through our Business Leaders Network
Platform created for continued growth and enhanced margins, based on a broadened product range and an exciting pipeline of new products
Xellia’s focus on R&D resulted in 15 new product filings in the year prior to our sale
Expanded Xellia's global manufacturing network including a fill-finish plant in Copenhagen and a manufacturing plant in China to secure low-cost supply